Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus priming regimen for venetoclax-resistant relapsed/refractory AML and high-risk MDS
ChiCTR2300076685Phase 4Recruiting
- Sponsor
- Hebei Provincial Hospital of Traditional Chinese Medicine
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of selinexor in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Hebei Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Complete response rate. Started Oct 2023; status: recruiting.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2300076685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076685.